Profile data is unavailable for this security.
About the company
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.
- Revenue in USD (TTM)162.87m
- Net income in USD23.49m
- Incorporated2016
- Employees160.00
- LocationEntrada Therapeutics IncOne Design Center Place, Suite 17-500BOSTON 02210United StatesUSA
- Phone+1 (857) 305-1825
- Fax+1 (302) 655-5049
- Websitehttps://www.entradatx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aerovate Therapeutics Inc | 0.00 | -82.19m | 502.71m | 51.00 | -- | 5.36 | -- | -- | -3.03 | -3.03 | 0.00 | 3.26 | 0.00 | -- | -- | 0.00 | -71.09 | -- | -80.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
| Compass Pathways PLC (ADR) | 0.00 | -129.44m | 504.65m | 186.00 | -- | 1.95 | -- | -- | -2.37 | -2.37 | 0.00 | 3.79 | 0.00 | -- | -- | 0.00 | -53.68 | -40.85 | -57.32 | -44.48 | -- | -- | -- | -- | -- | -43.34 | 0.1009 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| Adaptive Biotechnologies Corp | 174.50m | -215.06m | 508.42m | 709.00 | -- | 1.85 | -- | 2.91 | -1.48 | -1.48 | 1.20 | 1.87 | 0.2472 | 4.52 | 4.78 | 246,124.10 | -30.48 | -19.69 | -34.73 | -22.06 | 57.06 | 67.18 | -123.29 | -122.27 | 4.35 | -- | 0.3238 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
| Larimar Therapeutics Inc | 0.00 | -45.08m | 510.42m | 42.00 | -- | 2.21 | -- | -- | -0.9666 | -0.9666 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -24.56 | -42.22 | -26.04 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
| OmniAB Inc | 21.05m | -63.48m | 510.45m | 106.00 | -- | 1.69 | -- | 24.25 | -0.634 | -0.634 | 0.2103 | 2.57 | 0.055 | -- | 7.18 | 198,547.20 | -16.58 | -- | -17.48 | -- | -- | -- | -301.63 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| GeneDx Holdings Corp | 221.85m | -135.02m | 512.82m | 1.00k | -- | 2.47 | -- | 2.31 | -5.25 | -5.25 | 8.60 | 7.93 | 0.4721 | 9.16 | 7.27 | 221,849.00 | -28.73 | -- | -35.07 | -- | 50.57 | 11.50 | -60.86 | -121.10 | 2.99 | -130.27 | 0.2015 | -- | -13.69 | 8.72 | 67.98 | -- | 7.77 | -- |
| Avid Bioservices Inc | 136.74m | -18.26m | 513.55m | 365.00 | -- | 2.85 | -- | 3.76 | -0.2888 | -0.2888 | 2.17 | 2.84 | 0.302 | 3.18 | 4.89 | 374,616.40 | -4.03 | 10.70 | -6.13 | 15.18 | 7.47 | 22.72 | -13.35 | 25.86 | 0.3097 | -4.47 | 0.4548 | 0.00 | 24.81 | 22.72 | -99.80 | -- | 82.98 | -- |
| Astria Therapeutics Inc | 0.00 | -81.63m | 520.03m | 59.00 | -- | 1.91 | -- | -- | -2.32 | -2.32 | 0.00 | 6.70 | 0.00 | -- | -- | 0.00 | -27.34 | -64.48 | -28.18 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| Allogene Therapeutics Inc | 87.00k | -292.30m | 520.96m | 232.00 | -- | 0.9236 | -- | 5,988.05 | -1.78 | -1.78 | 0.0005 | 2.71 | 0.0001 | -- | -- | 375.00 | -43.85 | -28.46 | -47.04 | -30.21 | -- | -- | -335,973.60 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
| Entrada Therapeutics Inc | 162.87m | 23.49m | 522.25m | 160.00 | 24.66 | 1.93 | 19.49 | 3.21 | 0.6273 | 0.6273 | 4.79 | 8.02 | 0.3302 | -- | 3.89 | 1,024,359.00 | 4.76 | -- | 7.06 | -- | -- | -- | 14.42 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| PepGen Inc | 0.00 | -80.33m | 529.37m | 64.00 | -- | 2.95 | -- | -- | -3.25 | -3.25 | 0.00 | 5.53 | 0.00 | -- | -- | 0.00 | -39.37 | -- | -42.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Y-mAbs Therapeutics Inc | 84.50m | -21.67m | 530.98m | 100.00 | -- | 5.35 | -- | 6.28 | -0.496 | -0.496 | 1.93 | 2.26 | 0.6481 | 1.31 | 4.30 | 844,990.00 | -16.62 | -44.23 | -19.95 | -50.45 | 86.53 | -- | -25.64 | -181.13 | 5.67 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
| SIGA Technologies Inc | 157.02m | 79.26m | 532.00m | 45.00 | 6.82 | 3.22 | 6.66 | 3.39 | 1.10 | 1.10 | 2.20 | 2.32 | 0.7354 | 0.3631 | 10.32 | 3,489,424.00 | 37.12 | 22.34 | 47.49 | 27.56 | 87.71 | 88.65 | 50.48 | 41.14 | 2.19 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| Altimmune Inc | 410.00k | -92.77m | 532.48m | 59.00 | -- | 3.08 | -- | 1,298.72 | -1.59 | -1.59 | 0.007 | 2.44 | 0.0022 | -- | 1.47 | 6,949.15 | -49.42 | -39.62 | -53.14 | -42.58 | -- | -- | -22,626.10 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Kyverna Therapeutics Inc | 0.00 | -75.92m | 540.23m | 100.00 | -- | 1.50 | -- | -- | -1.73 | -1.73 | 0.00 | 8.37 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0045 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -99.34m | 541.44m | 75.00 | -- | 2.29 | -- | -- | -2.02 | -2.02 | 0.00 | 4.23 | 0.00 | -- | -- | 0.00 | -43.24 | -30.06 | -48.01 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
Data as of May 30 2024. Currency figures normalised to Entrada Therapeutics Inc's reporting currency: US Dollar USD
40.82%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 31 Mar 2024 | 4.87m | 14.45% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.73m | 8.10% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.31m | 3.90% |
| Redmile Group LLCas of 31 Mar 2024 | 1.28m | 3.81% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.05m | 3.13% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 1.03m | 3.05% |
| Geode Capital Management LLCas of 31 Mar 2024 | 475.36k | 1.41% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 435.39k | 1.29% |
| American Century Investment Management, Inc.as of 31 Mar 2024 | 366.35k | 1.09% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 198.77k | 0.59% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
